On August 16, the delegation of Guangzhou Bay Area Health Technology Achievement Transformation Growth Camp visited the headquarters building of Dunwill Medical for inspection and exchange. Guided by the Guangzhou Association for Science and Technology, the Growth Camp is an innovative learning program jointly initiated by the Guangzhou Suigangao High-Level Talents Achievement Transformation Promotion Association and other institutions. It brings together elite talents from three links in the achievement transformation chain, namely scientists, entrepreneurs, and full-chain professional service institutions. The program aims to strengthen exchanges and cooperation among various links in the technology achievement transformation chain, remove the "blockages" in technology achievement transformation, and accelerate the industrialization of China's scientific research achievements..

Liang Gaofeng, Second-Class Researcher of the Guangzhou Association for Science and Technology, Cao Ying, Director of the Science and Education Department of Dongguan Songshan Lake Central Hospital, Wen Qiwu, former Vice President of the Life and Health Center of Guangdong Zhongke Military-Civil Integration Industry Research Institute (who was associated with Wuhan Huoshenshan Hospital), Chen Bin, Executive President and Chairman of the Promotion Association, and other leaders and guests attended the event.

The delegation first visited the 1F exhibition hall and the warehousing and logistics area of Dunwill's headquarters building, gaining an in-depth understanding of the enterprise's founding mission, development history, and honorary achievements. Subsequently, the delegates further learned about the production and quality inspection environment of the enterprise's in vitro diagnostic reagents and spoke highly of the enterprise's quality management system. 

In the report session, Ms. Wen Dong, Chairman of Dunwill Medical, delivered a keynote speech entitled Walking with Dreams. Ms. Wen shared her cross-industry experience from a career as an athlete to an entrepreneur. As a former key player of the national women's epee team, she once won the national championship, the Asian Games team championship, and the individual third place in the World University Games, which forged her traits of accurate judgment, tenacious will, and flexible adaptability. Since founding Dunwill Medical in 2006, she has transformed her competitive spirit into business leadership: she led the team to focus on the research and development of original biomarkers and successfully launched the world's first molecular diagnostic product for liver cancer; in 2022, the company completed the first round of financing worth hundreds of millions of yuan; under her leadership, Dunwill has now become a world-leading company integrating original biomarker research and development with transformation throughout the entire process. Ms. Wen's business achievements have confirmed the commonality between "competition tactics" and "business strategies" — using information analysis for forward-looking layout, relying on pressure resistance to cope with risks, and seizing market opportunities with rapid response. She has always adhered to the original aspiration and dream of "serving Chinese doctors and patients with innovative biotechnology", committed to developing the company into an industry benchmark, and creating sustainable value for shareholders, employees, and society. 

Dr. Hou Ying, Executive Director of the Market & Strategic Development Center of Dunwill Medical, systematically introduced Dunwill Medical's innovative business model and product transformation system. He first elaborated on the company's unique closed-loop cooperation model of "Medical Research-R&D-Manufacturer". Starting from key clinical problems, this model adopts an innovative industry-university-research cooperation model where medical institutions lead technological research and development, and enterprises ensure production and product quality. It has successfully achieved efficient transformation from laboratory research to clinical products, and developed a number of original clinical-grade IVD products with independent intellectual property rights. In terms of competitive advantages, he compared the differences between traditional IVD enterprises and Dunwill, pointing out that the company's algorithm-driven Multi-omics Analysis and Assay (MAAA) technology not only avoids homogeneous competition of single biomarkers but also continuously optimizes product performance. He also showcased the company's full-stack R&D capabilities covering 8 major technology platforms such as molecular diagnosis, pathology, and mass spectrometry, as well as multiple IVD registration pipelines under advancement.He emphasized that compared with other IVD enterprises, Dunwill has demonstrated core competitiveness in the field of original product transformation, with advantages such as more comprehensive clinical research support capabilities, more flexible options for in vitro diagnostic product transformation, and more senior experience in original product declaration.

In the subsequent experience exchange session, both parties conducted enthusiastic and in-depth discussions on topics such as biomarker screening and product registration and declaration. The delegates stated that the concepts and practices of the Bay Area Health Technology Achievement Transformation Growth Camp and Dunwill Medical are highly consistent. They look forward to in-depth cooperation between the two sides in the field of technology achievement transformation in the future, jointly exploring new paths and models for technology achievement transformation, and contributing greater efforts to promoting high-quality economic and social development.

This exchange event has built a high-value communication platform. By in-depth analysis of the innovative path and successful experience of medical transformation under the "Dunwill Model", it has effectively promoted the collision of ideas and potential cooperation, injecting new impetus into jointly advancing the efficient transformation of medical and technological achievements and regional collaborative innovation. It is believed that through the "joint efforts" of clinical institutions, medical enterprises, experts and scholars, social capital, etc., more innovative achievements will be successfully transformed and implemented in the future.